Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
European Journal of Nuclear Medicine and Molecular Imaging|August 5, 2022
[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimatesFlorian Rosar, Andrea Schaefer-Schuler, Mark Bartholomä, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 16, 2017
Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid CancerMarika H Tesselaar, Thomas Crezee, Imke Schuurmans, et al.
Zeitschrift Fur Medizinische Physik|July 3, 2026
Limitations of Mono-Exponential Individual Fitting as a Reference Model for Single-Time-Point Dosimetry in [177Lu]Lu-PSMA-617 TherapyFulki Fiarka, Assyifa Rahman Hakim, Indra Budiansah, et al.
Theranostics|February 25, 2020
68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging studyWim van Boxtel, Susanne Lütje, Ilse C H van Engen-van Grunsven, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 10, 2023
Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177 Lu-PSMA-617 in prostate cancer patientsHinke Siebinga, Bastiaan M Privé, Steffie M B Peters, et al.
Nuclear Medicine Communications|January 4, 2023
Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D clinical dosimetryMaike J M Uijen, Bastiaan M Privé, Carla M L van Herpen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 4, 2021
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcomeSteffie M B Peters, Bastiaan M Privé, Maarten de Bakker, et al.
Pageof 10